Vegetation Management in Ontario's Forests: Survey Research of Public and Professional Perspectives

108 pagesOntario Ministry of Natural Resource

Incubation Period of Hantavirus Cardiopulmonary Syndrome

The potential incubation period from exposure to onset of symptoms was 7–39 days (median 18 days) in 20 patients with a defined period of exposure to Andes virus in a high-risk area. This period was 14–32 days (median 18 days) in 11 patients with exposure for <48 hours

Influence of laser ablation and plasma surface treatment on the joint strength of laser welded aluminum-polyamide assemblies

Laser assembly of a metal with a polymer is an innovative process for the development of hybrid lightweight structures. It was already demonstrated that surface treatment of aluminum prior to laser joining has a critical influence on joint strength of laser assembly with polyamide. In this work, further investigation of the influence of surface treatment prior to laser assembly is carried out. In particular, two kind of surface modification pretreatments of aluminum, laser ablation and plasma surface modification, in combination with plasma surface pretreatment of polyamide, were investigated. Surface properties of aluminum and polyamide after pretreatment are compared to their untreated state. More precisely, surface chemistry, surface energy and roughness characteristics are evaluated by X-ray photoelectron spectroscopy (XPS), sessile drop tests and 3D profilometry, respectively. Joint strength of laser assembly of treated aluminum and polyamide is reported. The more influential surface characteristics for the improvement of joint strength are determined, paving the way to significant advances in metal-polymer laser assembly technology

2020-04-16 DAILY UNM GLOBAL HEALTH COVID-19 BRIEFING

Executive Summary: Daily NM recap. Public Catholic masses resume. Chaplains stand down. Food delivered to tribal communities. Governors order face coverings use. Campfires restricted. NY hospitalizations fall. Nursing home probe in NJ. GOP call WHO Chief resignation. Africa cases up 51% and deaths up 60%. Sub-Saharan Africa prediction. Resurgence in Japan. UK conditions to reopen. France deaths up. UNMH protests over PPE. Med center financial stress. Hospitals bailout insufficient. 55% US healthcare worker cases hospital spread. Cruise ship transmission. Essential contact tracing. JAMA editors discuss policy. Guideline updates: treatment, emergency dep, ophthalmology, cath lab, telemedicine, liver disease, caregiver, health care facilities, FEMA, homeless services. Calcium channel blocker reduces fatality. Interferon lambda treatment. No benefit for lopinavir/ritonavir or arbidol in RCT. Donate plasma. Mixed results for antivirals on clearance. 37 new trials. Population-scale testing proposed. New rapid assay. Serology + RT-PCR needed. Hemoglobin monitoring. Co-infection of SARS-CoV-2. Urine glucose and proteinuria predict severity. Use damp cloth covers

2020-05-08 DAILY UNM GLOBAL HEALTH COVID-19 BRIEFING

Executive Summary: UNM drug repurposing. NM cases. Doctors Without Borders. SNAP benefits online. NM 7th highest unemployment. Virtual LemonAid tonight. New N98 masks. Healthcare supply chain challenge. EMS lack resources. Infection risk in healthcare workers. COVID-19 on medical education. Human disinfectant chambers. Evidence of seroconversion. Dangers of considering herd immunity. Wastewater-based surveillance. More youths infected. Reconstructing ship spread. Pharmacoepidemiologic analysis. Clinicopathologic characteristics. Cancer treatment impact. Reduced voluntary psychiatric admission in Italy. Operating room management. Humidifiers reduce transmission. Phone contact tracing ethics. Call for patient database. Immunity certification program. Guidelines on tracheostomy, IBD, nose bleeding, pituitary tumors, and hematopoietic stem cells transplantation, benefits of low-PEEP, and of molecular diagnostics. FDA authorizes at-home test. Cephid Xpert test. MRSA nasal swabs. NIH remdesivir+barictinib RCT. Corticosteroid caution. Arbidol active in vitro. ACE/ARB systematic review. In silico phytochemical and virus protease candidates. Potential zinc benefit. 31 new clinical trials. Glycemic control benefit. Psychological effects meta-analysis and survey. Disease course model. Liver injury. Environmental and health perspectives. Olfactory and gustatory dysfunction. Vitamin D. Disease map

First Human Isolate of Hantavirus (Andes virus) in the Americas

We isolated Andes virus (formal name: Andes virus [ANDV], a species in the genus Hantavirus), from serum of an asymptomatic 10-year-old Chilean boy who died 6 days later of hantavirus pulmonary syndrome (HPS). The serum was obtained 12 days after his grandmother died from HPS and 2 days before he became febrile. No hantavirus immunoglobulin (Ig) G or IgM antibodies were detected in the serum sample. After three blind passages, ANDV antigens were detected in Vero E6 cells by immunofluorescence assay and enzyme-linked immunosorbent assay, and ANDV RNA was detected by reverse transcription-polymerase chain reaction. A fragment of the virus genome showed 96.2% nucleotide identity with that of prototype ANDV. To our knowledge, this is the first isolation of any agent of hemorrhagic fever with renal syndrome from a human and the first such isolation of hantavirus before symptoms of that syndrome or HPS began

2020-04-24 DAILY UNM GLOBAL HEALTH COVID-19 BRIEFING

Executive Summary: NYT praises NM. NM Governor update. NM cases. NM antibody tests. State hiring freeze. Navajo Nation sues. Navajo Nation CA doctors. Mental health funding. Balloon Fiesta proceeding. Trump Lysol remarks. $484B business relief. 50k US deaths. US no to WHO initiatives. US crime reductions. Moscow 10% infections. Quebec elderly deaths. Italy psychiatric sequelae. Global vaccines summit. French nicotine sales restrictions. Adaptive cyclic exit strategies. Mask reuse techniques. Mask steaming method. Legionnaire’s reopening risks. Youth mental health. US disease models. Covid phobia treatment avoidance. Nursing home testing. Home nursing demand. CDC home cleaning. Guidelines on: convalescent plasma transfusion, H2O2 nasal use, pre-op testing, respiratory distress, ophthalmological practice, GI department reopening. FDA hydroxychloroquine cautions. Chloroquine high-dose mortality. HCQ+azithromycin long-QT. Iron reduction adjuvant. Repurposing prioritization. Pediatric HCQ dosing. HCQ enrollment up. 107 trials registered. PPE skin injuries. LDL and severity. 32 ECMO patients. Worse outcomes older monkeys

Prognosis of Atrial Fibrillation with or without Comorbidities: Analysis of Younger Adults from a Nationwide Database.

To assess the prognosis of AF patients with or without cardiac or extra-cardiac concomitant conditions. All consecutive patients diagnosed with AF admitted to French hospitals between 2011 and 2020 were identified. Patients were classified into four groups: (1) &gt; 60 yo; (2) with known cardiac disease (KCD group); (3) with extra-cardiac comorbidities (ECC); and 4) AF without KCD or ECC ("Lone AF"). Altogether 2,435,541 patients were identified, from which 2,203,702 patients aged &gt;60 years and 231,839 patients aged &lt;60 years (with KCD (55.2%), with ECC (14.7%) and with "Lone AF" (30.1%)). During follow-up, the incidences of all-cause and CV deaths were 13.7%, 5.7%, 6.2%, and 2.3%, and 4.2%, 1.7%, 0.8%, and 0.3% in the older than 60 yo group, KCD group, ECC group and "Lone AF" AF group, respectively. In the age and sex-adjusted analysis (patients &lt; 60 yo), patients with AF and KCD had worse outcomes than patients with "Lone AF" for all major cardiac events. There are three distinct prognostic criteria based on the presence or lack of HD or extra-cardiac concomitant comorbidities. Patients in the so-called "Lone AF" group remain severe in terms of CV events but still with a lower incidence than the patients with associated KCD or ECC. The presence of KCD or ECC makes it possible to distinguish a profile in terms of events that are very different between the patients

2020-05-02/03 DAILY UNM GLOBAL HEALTH COVID-19 BRIEFING

Executive Summary: More NM cases. Free Shiprock testing. Prison release demands. 8 state parks reopen. Higher US deaths. NY PPE case dismissed. Orthopedic Tx down. European deaths down. UK mortality factors. People leaving large cities. Ending lockdown strategies. Public mask impact. Taiwan tracing. Homeless shelter prevalence. Homeless shelter outbreak. 50-state R0. COVID-19 decades later. US county tracking site. Hospital management model. COVID-19 behavioral transformation. Practice guidelines for: cardiology, IBD surgery, and rheumatic physical inactivity. Roche antibody test approved. Abbott antibody test EU-certified. Home anosmia assessment. CVD and ACE/ARBs. Tocilizumab early evidence. Tocilizumab systematic review. WHO vaccines trial. HCQ slower viral clearance. CBC predicts severity. Kidney disease meta-analysis. Innate/adaptive immunity timing. Combating misinformation. Mental health living reviews

2020-04-30 DAILY UNM GLOBAL HEALTH COVID-19 BRIEFING

Executive Summary: NM residential facility deaths. NM case update. NM TriCore testing antibodies. Navajo nation cases. May 10 Navajo peak. Udall funding push. El Paso shopping discouraged. NM budget shortfall. Santa Fe furlough. Ethanol sanitizer safety. LA free testing for all. Michigan protest. NM Batelle N95 decontamination. Hospital revenue decline. Wastewater early detection. German herd immunity. 60-day viral shedding possible. Temporary infected “ark”. Prison release preparedness. Low quality research. Phased long-term care. Suicide prevention. Corticosteroid tradeoffs. Cloth mask guidelines. SARS-CoV-2 assays compared. IgG and viral loads. Better testing reporting. Dubious testing vendors. Promising oral drug. Hydroxychloroquine prophylaxis dosing. Umifenovir ineffective. Multi-drug nanoparticles. Drug discovery new targets. 38 new COVID-19 trials. Cancer research review. Attenuated SARS-CoV-2